660862-47-5

Basic information

• Product Name: 2-Piperazineethanol,(2S)-(9CI)
• Synonyms: 2-Piperazineethanol,(2S)-(9CI);(2S)-2-Piperazineethanol, dihydrochloride;(2S)-2-Piperazineethanol;2-[(2S)-piperazin-2-yl]ethanol;(S)-2-(piperazin-2-yl)ethanol
• CAS NO: 660862-47-5
• Molecular Formula: C₆H₁₄N₂O
• Molecular Weight: 130.19
• Product Categories: PIPERAZINE
• Mol File: 660862-47-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Piperazineethanol,(2S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Piperazineethanol,(2S)-(9CI)(660862-47-5)
• EPA Substance Registry System: 2-Piperazineethanol,(2S)-(9CI)(660862-47-5)

Safety Data

• Hazardous Substances Data: 660862-47-5(Hazardous Substances Data)

Upstream product

• 252873-54-4 benzyl 2-[(2S)-4-benzyl-3,6-dioxopiperazin-2-yl]acetate 
• 321918-75-6 benzyl (3S)-4-[benzyl-(2-ethoxy-2-oxoethyl)amino]-3-(tert-butoxycarbonylamino)-4-oxobutanoate 
• 477220-33-0 2-[(2S)-4-benzylpiperazin-2-yl]ethanol 
• 660862-43-1 (S)-2-(1,4-dibenzylpiperazin-2-yl)ethanol 
• 52661-95-7 (S)-ethyl 2-(3,6-dioxopiperazin-2-yl)acetate 

Downstream Products

• 1334483-05-4 (S)-tert-butyl 3-(4-benzoyl-2-(2-hydroxyethyl)piperazin-1-yl)propanoate 
• 1334482-99-3 C₂₀H₂₈N₂O₃ 
• 764714-59-2 ((7R,9aS)-octahydro-1H-pyrido[1,2-a]pyrazin-7-yl)methanol 
• 1045863-73-7 dibenzyl (2S)-2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate 
• 660862-48-6 (S)-2-(2-hydroxyethyl)piperazine-1,4-dicarboxylic acid di-tert-butyl ester 

Relevant articles and documents

KRAS G12C INHIBITORS

The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS

Therapeutic combinations of hepatitis B virus (HBV) vaccines and capsid assembly modulators (CAMs), such as dihydropyrimidine derivatives are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described.

Synthesis of a bicyclic piperazine from l-aspartic acid and application of a fluoride-promoted SNAr coupling

The process development is reported of a pivotal C-N bond formation involving ((7R,9aS)-octahydro-1H-pyrido[1,2-a]pyrazin-7-yl)methanol (2) undergoing nucleophilic aromatic substitution with 3-chlorobenzo[d]isoxazole (3) to furnish ((7R,9aS)-2-(benzo[d]isoxazol-3-yl)octahydro-1H-pyrido[1,2-a] pyrazin-7-yl)methanol (4) as a key intermediate for a family of compounds (1). Essential to the success of the coupling is the use of fluoride in combination with a phase transfer catalyst. The development of an alternative route to bicyclic piperazine 2 that uses l-aspartic acid (20) as a starting material to avoid the need for a classical salt resolution is described.